Cardio-renal interaction - Clinical trials update 2022

•This review summarizes clinically relevant studies on the cardio-renal interaction published in 2021 and 2022.•Finerenone was shown to be effective and safe in patients with moderate to severe diabetic chronic kidney disease•Dapagliflozin and empagliflozin reduce mortality and morbidity in patients with HF across the whole spectrum of renal function•Chlorthalidone is also effective and safe in the treatment of arterial hypertension in patients with severe CKD•Infective endocarditis in patients receiving chronic hemodialysis is associated with high mortality, especially if some specific risk factors (such as central nervous system embolism, persistent bacteremia, other embolism and AHF) are present•Etelcalcetide decreases FGF23 levels, a mediator of cardiac remodeling, and thus can reduce left ventricular hypertrophy progression in patients with end stage kidney disease